Analytical Data
-
Gene name
BMP7
- Application
-
Alternative Names
BMP7；OP1；Bone morphogenetic Protein 7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P18075
-
Expression Region
315-431aa
-
AA Sequence
MANVAENSSSDQRQACKKHELYVSFRDLGWQDWIIAPEGYAAYYCEGECA FPLNSYMNATNHAIVQTLVHFINPETVPKPCCAPTQLNAISVLYFDDSSN VILKKYRNMVVRACGCH
-
Molecular Weight
26 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Bone morphogenetic protein 7 (BMP7), also known as osteogenic protein 1 (OP-1), is part of the transforming growth factor-beta (TGF-β) superfamily, playing a crucial role in bone formation and repair, as well as in various cellular processes such as differentiation and tissue homeostasis. Research on BMP7 has gained significant attention due to its potential therapeutic applications in regenerative medicine, particularly in orthopedic applications and the treatment of fractures, osteoarthritis, and other bone-related disorders. Recombinant BMP7 protein has been explored extensively for its ability to stimulate osteogenesis by promoting the differentiation of mesenchymal stem cells into osteoblasts, the cells responsible for bone formation. Moreover, BMP7 has demonstrated anti-inflammatory properties, making it a promising candidate for treating conditions characterized by excessive inflammation and tissue damage. The production of recombinant BMP7 in various expression systems, including bacteria, yeast, and mammalian cells, has facilitated its study and potential clinical applications. However, challenges remain in achieving optimal protein yield, bioactivity, and stability, necessitating ongoing research into its molecular mechanisms and interactions within the bone microenvironment. Understanding these factors can help enhance the efficacy and safety of BMP7-based therapies, paving the way for innovative treatments in orthopedic and regenerative medicine.
